Directorate Change

Deltex Medical Group PLC
11 July 2002

11 July 2002



            Deltex Medical Group plc ('Deltex Medical' / 'Company')



                            APPOINTMENT OF DIRECTOR


Chichester, UK - Deltex Medical (AIM LSE: DEMG) today announces the appointment
of Daniel Bretonneau to the Board as Sales Director with immediate effect.  His
key responsibilities are for global sales and strategic alliances, in particular
with Deltex Medical's international network of distribution partners.



Daniel, aged 54, has over 25 years' experience in the sales and marketing of
medical equipment for intensive care and operating rooms throughout Europe, the
Middle East and Asia and has worked for a variety of companies, including ATM
Medishield, Air Liquide Group, Physio Control, Bruker and Novametrix.  He joined
Deltex Medical in June 1999 and was promoted to Head of Sales in July 2001.
Daniel is the main point of contact for all of Deltex Medical's distributor
partners worldwide and has played a key role in Deltex Medical's initial market
penetration and subsequent growth in Europe, Latin America and the Far East.



Commenting on the appointment, Nigel Keen, Chairman of Deltex Medical, said:



'The appointment of Daniel Bretonneau recognises his valuable contribution to
Deltex Medical's progress to date.  This appointment has been made at a key
stage in the Company's growth as we continue to develop strategies to match the
quality and potential of our technology.'



Daniel Bretonneau commented:



'I am particularly thrilled to be joining the Deltex Medical Board at this stage
in the Company's development.  Deltex Medical is unique amongst young medical
device businesses in my experience - its technology is proven and the proof is
well documented; it enjoys vigorous support from pre-eminent clinicians in many
countries; it has a substantial installed base; the devices are well built and
extremely reliable; we have well established relationships with some high
quality distribution partners and are building our own sales and marketing
resources to complement these considerable competitive advantages.  Most
importantly of all, Deltex Medical's products already help over 50 patients a
day get better, quicker.'



Daniel is also a Director of Sidus International Limited.  There are no other
matters to be disclosed under schedule two, paragraph (f) of the AIM Rules.



                                    - ends -





For further information



Deltex Medical Group plc

Tel: [phone]



Nigel Keen, Chairman and Chief Executive

[e-mail]

Ewan Phillips, Finance Director

[e-mail]







Financial Dynamics

Tel: [phone]



Stephanie Highett

[e-mail]

Sarah Mehanna

[e-mail]







Notes for editors



Deltex Medical primarily develops, assembles and markets a cardiac function
monitor and therapy guidance device, the CardioQ ('CardioQ'/'Monitor'). The
CardioQ incorporates the Company's proprietary software and a narrow,
easy-to-use, minimally invasive, disposable oesophageal probe, used for
transmitting and receiving an ultra-sound ('Doppler') signal. By using this
Doppler technology, the CardioQ provides clinicians with an early warning on the
haemodynamic condition of critically ill patients. This continuous, real-time
monitoring facilitates the administration of fluids or drugs in a timely fashion
and provides an immediate assessment of their impact.



There are already over 600 CardioQs currently in use in hospitals worldwide and
distribution arrangements are in place in over 30 countries. In addition, there
are currently more than 75 clinical publications on the use of the CardioQ which
have repeatedly:-



  • validated the results of the Monitor against known standards for measuring
    cardiac output, demonstrating that the technology works
  • proved that the CardioQ works over a variety of types of operation
  • shown that the Company's technology provides significant health and
    economic benefits by helping to reduce post-operative complications and
    length of hospital stays by an average of 30 to 40 per cent for a wide range
    of patients.



The Company is also currently developing a number of new products:-



  • The SupraQ - a monitor based on the CardioQ technology but using a
    completely non-invasive probe; the prototype is being prepared for clinical
    testing in the second half of 2002
  • The NeuroQ - a monitor designed to measure blood flow in the brain; the
    new prototype is in preparation for clinical trials in the second half of
    2002



The Company has recently completed development of a multi-patient probe for use
in specific circumstances in certain markets; the multi-patient probe for use in
operating theatres in the UK was launched in July 2002.



                      This information is provided by RNS
            The company news service from the London Stock Exchange